Table of Contents Author Guidelines Submit a Manuscript
Journal of Pathogens
Volume 2017, Article ID 7349268, 10 pages
https://doi.org/10.1155/2017/7349268
Review Article

Epstein-Barr Virus as a Promising Immunotherapeutic Target for Nasopharyngeal Carcinoma Treatment

1Sunway Institute for Healthcare Development (SIHD), Sunway University, Jalan Universiti, Bandar Sunway, 47500 Subang Jaya, Selangor Darul Ehsan, Malaysia
2Anatomical Pathology Department, Sunway Medical Centre, Jalan Lagoon Selatan, Bandar Sunway, 47500 Subang Jaya, Selangor Darul Ehsan, Malaysia

Correspondence should be addressed to Sin-Yeang Teow; ym.ude.yawnus@tdlanor

Received 31 August 2017; Accepted 9 December 2017; Published 31 December 2017

Academic Editor: Mario M. D’Elios

Copyright © 2017 Sin-Yeang Teow et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. M. Lieberman, “Epstein-Barr virus turns 50,” Science, vol. 343, no. 6177, pp. 1323–1325, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. L. S. Young, L. F. Yap, and P. G. Murray, “Epstein-Barr virus: More than 50 years old and still providing surprises,” Nature Reviews Cancer, vol. 16, no. 12, pp. 789–802, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. J. I. Cohen, E. S. Mocarski, N. Raab-Traub, L. Corey, and G. J. Nabel, “The need and challenges for development of an epstein-barr virus vaccine,” Vaccine, vol. 31, no. 2, pp. B194–B196, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Y. Teow and S. C. Peh, “Exosomes as the promising biomarker for Epstein-Barr virus (EBV)-associated cancers,” in Novel Implications of Exosomes in Diagnosis And Treatment of Cancer And Infectious Diseases, J. Wang, Ed., In Tech., 2017. View at Google Scholar
  5. S.-W. Tsao, C. M. Tsang, K.-F. To, and K.-W. Lo, “The role of Epstein-Barr virus in epithelial malignancies,” The Journal of Pathology, vol. 235, no. 2, pp. 323–333, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. S. W. Tsao, G. Tramoutanis, C. W. Dawson, A. K. F. Lo, and D. P. Huang, “The significance of LMP1 expression in nasopharyngeal carcinoma,” Seminars in Cancer Biology, vol. 12, no. 6, pp. 473–487, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. Q.-L. Kong, L.-J. Hu, J.-Y. Cao et al., “Epstein-barr virus-encoded LMP2A induces an epithelial- mesenchymal transition and increases the number of side population stem-like cancer cells in nasopharyngeal carcinoma,” PLoS Pathogens, vol. 6, no. 6, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. M. S. Kang and E. Kieff, “Epstein–Barr virus latent genes,” Experimental Molecular Medicine, vol. 47, no. 1, p. e131, 2015. View at Google Scholar
  9. L. Hu, Z. Lin, Y. Wu et al., “Comprehensive profiling of EBV gene expression in nasopharyngeal carcinoma through paired-end transcriptome sequencing,” Frontiers of Medicine, vol. 10, no. 1, pp. 61–75, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. S.-Y. Huang, C.-Y. Fang, C.-H. Tsai et al., “N-methyl-N-nitro-N-nitrosoguanidine induces and cooperates with 12-O-tetradecanoylphorbol-1,3-acetate/sodium butyrate to enhance Epstein-Barr virus reactivation and genome instability in nasopharyngeal carcinoma cells,” Chemico-Biological Interactions, vol. 188, no. 3, pp. 623–634, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. G. K. Hong, P. Kumar, L. Wang et al., “Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines,” Journal of Virology, vol. 79, no. 22, pp. 13984–13992, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Li, S. Liu, J. Hu et al., “Epstein-Barr virus lytic reactivation regulation and its pathogenic role in carcinogenesis,” International Journal of Biological Sciences, vol. 12, no. 11, pp. 1309–1318, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. S. D. Stoker, Z. Novalić, M. A. Wildeman et al., “Epstein–Barr virus-targeted therapy in nasopharyngeal carcinoma,” Journal of Cancer Research and Clinical Oncology, vol. 141, no. 10, pp. 1845–1857, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Cao, “EBV based cancer prevention and therapy in nasopharyngeal carcinoma,” Nature Partner Journals Precision Oncology, vol. 1, no. 1, p. 10, 2017. View at Publisher · View at Google Scholar
  15. V. P. Lutzky, P. Crooks, L. Morrison et al., “Cytotoxic T cell adoptive immunotherapy as a treatment for nasopharyngeal carcinoma,” Clinical and Vaccine Immunology, vol. 21, no. 2, pp. 256–259, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. M.-C. Lin, Y.-C. Lin, S.-T. Chen, T.-H. Young, and P.-J. Lou, “Therapeutic vaccine targeting Epstein-Barr virus latent protein, LMP1, suppresses LMP1-expressing tumor growth and metastasis in vivo,” BMC Cancer, vol. 17, no. 1, article no. 18, 2017. View at Publisher · View at Google Scholar · View at Scopus
  17. G. S. Taylor and N. M. Steven, “Therapeutic vaccination strategies to treat nasopharyngeal carcinoma,” Chinese Clinical Oncology, vol. 5, no. 2, article no. 23, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. J. I. Cohen, “EpsteinBarr virus vaccines,” Clinical Translational Immunology, vol. 4, no. 1, p. e32, 2015. View at Google Scholar
  19. G. S. Taylor, H. Jia, K. Harrington et al., “A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: A phase I trial in UK patients with EBV-positive cancer,” Clinical Cancer Research, vol. 20, no. 19, pp. 5009–5022, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. E. P. Hui, G. S. Taylor, H. Jia et al., “Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients,” Cancer Research, vol. 73, no. 6, pp. 1676–1688, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Wu, D. Xu, Q. Cheng, L. Zhang, D. Cheng, and J. Zhao, “EBV LMP1 regulates cancer growth through IRF-7 in nasopharyngeal carcinoma,” Journal of Molecular Oncology Research, vol. 1, no. 1, pp. 47–52, 2017. View at Google Scholar
  22. R. J. Port, S. Pinheiro-Maia, C. Hu et al., “Epstein-Barr virus induction of the Hedgehog signalling pathway imposes a stem cell phenotype on human epithelial cells,” The Journal of Pathology, vol. 231, no. 3, pp. 367–377, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. C. W. Dawson, R. J. Port, and L. S. Young, “The role of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC),” Seminars in Cancer Biology, vol. 22, no. 2, pp. 144–153, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Horikawa, T.-S. Sheen, H. Takeshita, H. Sato, M. Furukawa, and T. Yoshizaki, “Induction of c-met proto-oncogene by Epstein-Barr virus latent membrane protein-1 and the correlation with cervical lymph node metastasis of nasopharyngeal carcinoma,” The American Journal of Pathology, vol. 159, no. 1, pp. 27–33, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. Y.-Y. Lan, J.-R. Hsiao, K.-C. Chang et al., “Epstein-barr virus latent membrane protein 2A promotes invasion of nasopharyngeal carcinoma cells through ERK/Fra-1-mediated induction of matrix metalloproteinase 9,” Journal of Virology, vol. 86, no. 12, pp. 6656–6667, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. J. A. Fotheringham, N. E. Coalson, and N. Raab-Traub, “Epstein-barr virus latent membrane protein-2a induces ITAM/syk- and akt-dependent epithelial migration through αV-integrin membrane translocation,” Journal of Virology, vol. 86, no. 19, pp. 10308–10320, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. J. A. Fotheringham, S. Mazzucca, and N. Raab-Traub, “Epstein-Barr virus latent membrane protein-2A-induced Δnp63α expression is associated with impaired epithelial-cell differentiation,” Oncogene, vol. 29, no. 30, pp. 4287–4296, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Fukuda and R. Longnecker, “Latent Membrane Protein 2A Inhibits Transforming Growth Factor-β1-Induced Apoptosis through the Phosphatidylinositol 3-Kinase/Akt Pathway,” Journal of Virology, vol. 78, no. 4, pp. 1697–1705, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. G. A. Moody, R. S. Scott, N. Amirghahari et al., “Modulation of the cell growth regulator mTOR by Epstein-Barr virus-encoded LMP2A,” Journal of Virology, vol. 79, no. 9, pp. 5499–5506, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. L. Frappier, “Role of EBNA1 in NPC tumourigenesis,” Seminars in Cancer Biology, vol. 22, no. 2, pp. 154–161, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. N. Sivachandran, F. Sarkari, and L. Frappier, “Epstein-Barr nuclear antigen 1 contributes to nasopharyngeal carcinoma through disruption of PML nuclear bodies,” PLoS Pathogens, vol. 4, no. 10, Article ID e1000170, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. V. H. J. Wood, J. D. O'Neil, W. Wei, S. E. Stewart, C. W. Dawson, and L. S. Young, “Epstein-Barr virus-encoded EBNA1 regulates cellular gene transcription and modulates the STAT1 and TGFβ signaling pathways,” Oncogene, vol. 26, no. 28, pp. 4135–4147, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Y. Cao, S. Mansouri, and L. Frappier, “Changes in the nasopharyngeal carcinoma nuclear proteome induced by the EBNA1 protein of epstein-barr virus reveal potential roles for EBNA1 in metastasis and oxidative stress responses,” Journal of Virology, vol. 86, no. 1, pp. 382–394, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Hsu, S.-Y. Wu, S.-S. Chang et al., “Epstein-Barr virus lytic transactivator Zta enhances chemotactic activity through induction of interleukin-8 in nasopharyngeal carcinoma cells,” Journal of Virology, vol. 82, no. 7, pp. 3679–3688, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. C.-C. Wu, M.-T. Liu, Y.-T. Chang et al., “Epstein-Barr Virus DNase (BGLF5) induces genomic instability in human epithelial cells,” Nucleic Acids Research, vol. 38, no. 6, Article ID gkp1169, pp. 1932–1949, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. S.-H. Chiu, C.-C. Wu, C.-Y. Fang et al., “Epstein-Barr virus BALF3 mediates genomic instability and progressive malignancy in nasopharyngeal carcinoma,” Oncotarget , vol. 5, no. 18, pp. 8583–8601, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Takada, “Role of EBER and BARF1 in nasopharyngeal carcinoma (NPC) tumorigenesis,” Seminars in Cancer Biology, vol. 22, no. 2, pp. 162–165, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. D. Elgui de Oliveira, B. G. Müller-Coan, and J. S. Pagano, “Viral Carcinogenesis Beyond Malignant Transformation: EBV in the Progression of Human Cancers,” Trends in Microbiology, vol. 24, no. 8, pp. 649–664, 2016. View at Publisher · View at Google Scholar · View at Scopus
  39. C. Smith, N. Wakisaka, T. Crough et al., “Discerning regulation of cis- and trans-presentation of CD8+ T-cell epitopes by EBV-encoded oncogene LMP-1 through self-aggregation,” Blood, vol. 113, no. 24, pp. 6148–6152, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. L. Frappier, “EBNA1,” Current Topics in Microbiology and Immunology, vol. 391, pp. 3–34, 2015. View at Publisher · View at Google Scholar · View at Scopus
  41. K. Bickham, C. Münz, M. L. Tsang et al., “EBNA1-specific CD4+ T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function,” The Journal of Clinical Investigation, vol. 107, no. 1, pp. 121–130, 2001. View at Publisher · View at Google Scholar · View at Scopus
  42. S. P. Lee, J. M. Brooks, H. Al-Jarrah et al., “CD8 T cell recognition of endogenously expressed Epstein-Barr virus nuclear antigen 1,” The Journal of Experimental Medicine, vol. 199, no. 10, pp. 1409–1420, 2004. View at Publisher · View at Google Scholar · View at Scopus
  43. M.-H. Tsai, A. Raykova, O. Klinke et al., “Spontaneous Lytic Replication and Epitheliotropism Define an Epstein-Barr Virus Strain Found in Carcinomas,” Cell Reports, vol. 5, no. 2, pp. 458–470, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. X. Lin, M.-H. Tsai, A. Shumilov et al., “The Epstein-Barr Virus BART miRNA Cluster of the M81 Strain Modulates Multiple Functions in Primary B Cells,” PLoS Pathogens, vol. 11, no. 12, Article ID e1005344, 2015. View at Publisher · View at Google Scholar · View at Scopus
  45. M.-H. Tsai, X. Lin, A. Shumilov et al., “The biological properties of different Epstein-Barr virus strains explain their association with various types of cancers,” Oncotarget , vol. 8, no. 6, pp. 10238–10254, 2017. View at Publisher · View at Google Scholar · View at Scopus
  46. K. F. Hui, D. N. Ho, C. M. Tsang, J. M. Middeldorp, G. S. W. Tsao, and A. K. S. Chiang, “Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma,” International Journal of Cancer, vol. 131, no. 8, pp. 1930–1940, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. C. K. Choi, D. N. Ho, K. F. Hui, R. Y. Kao, and A. K. S. Chiang, “Identification of novel small organic compounds with diverse structures for the induction of Epstein-Barr Virus (EBV) lytic cycle in EBV-positive epithelial malignancies,” PLoS ONE, vol. 10, no. 12, Article ID e0145994, 2015. View at Publisher · View at Google Scholar · View at Scopus
  48. Z. Novalić, T. M. Rossen, A. E. Greijer, and J. M. Middeldorp, “Agents and approaches for lytic induction therapy of epstein-barr virus associated malignancies,” Medicinal Chemistry (Los Angeles), vol. 6, pp. 449–466, 2016. View at Google Scholar
  49. C. U. Louis, K. Straath, C. M. Bollard et al., “Enhancing the in vivo expansion of adoptively transferred EBV- Specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients,” Blood, vol. 113, no. 11, pp. 2442–2450, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Jain, W. K. Chia, and H. C. Toh, “Immunotherapy for nasopharyngeal cancer-A review,” Chinese Clinical Oncology, vol. 5, no. 2, article no. 22, 2016. View at Publisher · View at Google Scholar · View at Scopus
  51. C. U. Louis, K. Straathof, C. M. Bollard et al., “Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma,” Journal of Immunotherapy, vol. 33, no. 9, pp. 983–990, 2010. View at Google Scholar
  52. S. Secondino, M. Zecca, L. Licitra et al., “T-cell therapy for EBV-associated nasopharyngeal carcinoma: Preparative lymphodepleting chemotherapy does not improve clinical results,” Annals of Oncology, vol. 23, no. 2, pp. 435–441, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. C. Smith, V. Lee, A. Schuessler et al., “Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: Phenotype and effector function of T cells impact on clinical response,” OncoImmunology, vol. 6, no. 2, Article ID e1273311, 2017. View at Publisher · View at Google Scholar · View at Scopus
  54. C. Smith, J. Tsang, L. Beagley et al., “Effective treatment of metastatic forms of epstein-barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy,” Cancer Research, vol. 72, no. 5, pp. 1116–1125, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. W.-K. Chia, M. Teo, W.-W. Wang et al., “Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma,” Molecular Therapy, vol. 22, no. 1, pp. 132–139, 2014. View at Publisher · View at Google Scholar · View at Scopus
  56. W. K. Chia, W.-W. Wang, M. Teo et al., “A phase II study evaluating the safety and efficacy of an adenovirus-δLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma,” Annals of Oncology, vol. 23, no. 4, pp. 997–1005, 2012. View at Publisher · View at Google Scholar · View at Scopus
  57. C.-L. Lin, W.-F. Lo, T.-H. Lee et al., “Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma,” Cancer Research, vol. 62, no. 23, pp. 6952–6958, 2002. View at Google Scholar · View at Scopus
  58. J. S. Weber, J. C. Yang, M. B. Atkins, and M. L. Disis, “Toxicities of immunotherapy for the practitioner,” Journal of Clinical Oncology, vol. 33, no. 18, pp. 2092–2099, 2015. View at Publisher · View at Google Scholar · View at Scopus
  59. L. Yang, H. Yu, S. Dong, Y. Zhong, and S. Hu, “Recognizing and managing on toxicities in cancer immunotherapy,” Tumor Biology, vol. 39, no. 3, 2017. View at Publisher · View at Google Scholar · View at Scopus
  60. I. Satti, J. Meyer, S. A. Harris et al., “Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: A phase 1, double-blind, randomised controlled trial,” The Lancet Infectious Diseases, vol. 14, no. 10, pp. 939–946, 2014. View at Publisher · View at Google Scholar · View at Scopus
  61. D.-S. Chung, C.-H. Kim, and Y.-K. Hong, “Animal models for vaccine therapy,” Advances in Experimental Medicine and Biology, vol. 746, pp. 143–150, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. P. Busson, G. Ganem, P. Flores et al., “Establishment and characterization of three transplantable EBV‐containing nasopharyngeal carcinomas,” International Journal of Cancer, vol. 42, no. 4, pp. 599–606, 1988. View at Publisher · View at Google Scholar · View at Scopus
  63. S. L. Hoe, L. P. Tan, N. Abdul Aziz et al., “CD24, CD44 and EpCAM enrich for tumour-initiating cells in a newly established patient-derived xenograft of nasopharyngeal carcinoma,” Scientific Reports, vol. 7, no. 1, 12372 pages, 2017. View at Publisher · View at Google Scholar
  64. S. L. L. Hoe, L. P. Tan, J. Jamal et al., “Evaluation of stem-like side population cells in a recurrent nasopharyngeal carcinoma cell line,” Cancer Cell International, vol. 14, no. 1, article no. 101, 2014. View at Publisher · View at Google Scholar · View at Scopus
  65. P. A. Smith, D. Merritt, L. Barr, and D. A. Thorley-Lawson, “An orthotopic model of metastatic nasopharyngeal carcinoma and its application in elucidating a therapeutic target that inhibits metastasis,” Genes & Cancer, vol. 2, no. 11, pp. 1023–1033, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. T. Fu, S. V. Kui, and R.-F. Wang, “Critical role of EBNA1-specific CD4+ T colls in the control of mouse Burkitt lymphoma in vivo,” The Journal of Clinical Investigation, vol. 114, no. 4, pp. 542–550, 2004. View at Publisher · View at Google Scholar · View at Scopus
  67. J. Li, Q.-Y. Chen, J. He et al., “Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma,” OncoImmunology, vol. 4, no. 2, pp. 1–10, 2015. View at Publisher · View at Google Scholar · View at Scopus
  68. P. Szturz and J. B. Vermorken, “Immunotherapy in head and neck cancer: aiming at EXTREME precision,” BMC Medicine, vol. 15, no. 1, p. 110, 2017. View at Publisher · View at Google Scholar
  69. A. W. M. Lee, B. B. Y. Ma, W. T. Ng, and A. T. C. Chan, “Management of nasopharyngeal carcinoma: current practice and future perspective,” Journal of Clinical Oncology, vol. 33, no. 29, pp. 3356–3364, 2015. View at Publisher · View at Google Scholar · View at Scopus
  70. S. C. Kenney and J. E. Mertz, “Regulation of the latent-lytic switch in Epstein-Barr virus,” Seminars in Cancer Biology, vol. 26, pp. 60–68, 2014. View at Publisher · View at Google Scholar · View at Scopus
  71. L. S. Young and C. W. Dawson, “Epstein-Barr virus and nasopharyngeal carcinoma,” Chinese Journal of Cancer, vol. 33, no. 12, pp. 581–590, 2014. View at Publisher · View at Google Scholar · View at Scopus
  72. K. Houali, X. Wang, Y. Shimizu et al., “A new diagnostic marker for secreted Epstein-Barr virus-encoded LMP1 and BARF1 oncoproteins in the serum and saliva of patients with nasopharyngeal carcinoma,” Clinical Cancer Research, vol. 13, no. 17, pp. 4993–5000, 2007. View at Publisher · View at Google Scholar · View at Scopus
  73. K. A. Chan, J. K. Woo, A. King et al., “Analysis of Plasma Epstein–Barr Virus DNA to Screen for Nasopharyngeal Cancer,” The New England Journal of Medicine, vol. 377, no. 6, pp. 513–522, 2017. View at Publisher · View at Google Scholar
  74. S. Teow, K. Liew, A. S. Khoo, and S. Peh, “Pathogenic role of exosomes in epstein-barr virus (ebv)-associated cancers,” International Journal of Biological Sciences, vol. 13, no. 10, pp. 1276–1286, 2017. View at Publisher · View at Google Scholar
  75. T. R. Rebbeck, “Precision prevention of cancer,” Cancer Epidemiology, Biomarkers & Prevention, vol. 23, no. 12, pp. 2713–2715, 2014. View at Publisher · View at Google Scholar · View at Scopus
  76. F.-H. Xu, D. Xiong, Y.-F. Xu et al., “An epidemiological and molecular study of the relationship between smoking, risk of nasopharyngeal carcinoma, and epsteinbarr virus activation,” Journal of the National Cancer Institute, vol. 104, no. 18, pp. 1396–1410, 2012. View at Publisher · View at Google Scholar · View at Scopus
  77. Y. Shi, S. L. Peng, L. F. Yang, X. Chen, Y. G. Tao, and Y. Cao, “Co-infection of Epstein barr virus and human papillomavirus in human tumorigenesis,” Chinese Journal of Cancer, vol. 35, p. 16, 2016. View at Google Scholar